Disruptors in the PsO and PsA Market: Weighing Clearance, Convenience and Cost

By: Vania Galarraga, MPH, Engagement ManagerSkin diseases constitute one of the leading causes of health burden worldwide, measured as disability-adjusted life years (DALYs). Among skin diseases, psoriasis (PsO) carries the third-largest disability weight, which translates into health loss and poor quality of life (QoL)1. Globally, approximately 1-8% of the population suffers from PsO2, 3. Among PsO patients, the prevalence of psoriatic arthritis (PsA) is estimated to be between 6% and 41%3.

EGFR-Mutation-Positive NSCLC: Choosing the Best Therapeutic Strategy

By: Nick Turner, PhD, Senior Director Activating mutations in the EGFR gene are found in about 10-12% of all non-small cell lung cancer (NSCLC) cases and around 50% of cases in East-Asian patients. Cancer in patients with mutations is driven by constitutive activation of EGFR-signaling pathways due to acquired mutations in the catalytic domain of the receptor rendering them amenable to EGFR-tyrosine kinase inhibition1.

Strategic Brand Planning: Winning by Resource Optimization

Our client was a global biopharmaceutical company with a market-leading brand more than 20 years’ old. It came under intense pricing pressure due to generic entries from companies known to play primarily on price.

1 2 3 5